Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry

Qiao-Gen Zou; Xiao-Heng Tan; Wen-Jun Che; Zun-Jian Zhang; Ping Wei; Ping-Kai Ou-Yang

doi:10.1055/s-0031-1296210

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2011; 61(6): 353-357
DOI: 10.1055/s-0031-1296210

Anticoagulants · Antithrombotics · Anti-varicosis Drugs · Blood Flow Stimulants

Editio Cantor Verlag Aulendorf (Germany)

Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry

Qiao-Gen Zou

¹Biology and Pharmacy Engineer Department, Nanjing University of Technology, Nanjing, (P. R. China)

²Center for Instrumental Analysis, China Pharmaceutical University, Nanjing, (P. R. China)

,

Xiao-Heng Tan

²Center for Instrumental Analysis, China Pharmaceutical University, Nanjing, (P. R. China)

,

Wen-Jun Che

³Administration for Products Quality Supervision and Inspection of Jiangsu Province, Nanjing, (P. R. China)

,

Zun-Jian Zhang

²Center for Instrumental Analysis, China Pharmaceutical University, Nanjing, (P. R. China)

,

Ping Wei

¹Biology and Pharmacy Engineer Department, Nanjing University of Technology, Nanjing, (P. R. China)

,

Ping-Kai Ou-Yang

¹Biology and Pharmacy Engineer Department, Nanjing University of Technology, Nanjing, (P. R. China)

› Author Affiliations

Abstract

The bioavailability of clopidogrel bisulfate (CAS 135046-48-9) form I was compared with that of Clopidogrel bisulfate form II in 12 male Sprague-Dawley rats. The rats, randomly divided into two groups, received a single oral dose of 8 mg/kg Clopidogrel (CP) bisulfate form I and form II, respectively, under fasting condition. The plasma concentrations of CP and its inactive carboxylic acid metabolite (CAS 144457-28-3, IM) were simultaneously determined by a sensitive, specific LC-MS/MS method. The pharmacokinetic parameters included C_max, T_max, t_1/2, AUC_0–t AUC_0–∞. The AUC_0–∞ of CP was 13.78 ± 0.67 and 11.46 ± 1.98 ng/mL · h for CP form I and form II, respectively. The AUC_0–∞ of IM was 33.08 ± 5.76 and 21.67 ± 8.95 μg/mL · h for CP form I and form II, respectively. The maximum plasma concentration (C_max) of CP was 3.81 ± 0.54 ng/mL for CP form I and 3.18 ± 0.31 ng/mL for CP form II, the C_max of IM was 3.42 ± 0.41 and 2.08 ± 0.68 μg/mL for the CP form I and form II, respectively. There was an obvious difference between form I and form II for C_max and the area under the plasma concentration time curve for both CP and IM after a t-test. This study shows that CP form I has better bioavailability in rats than CP form II.

Key words

Antiplatelet drug - Bioavailability - Clopidogrel bisulfate - Clopidogrel carboxylic acid metabolite - LC-MS/MS - Solid form

Full Text

References

References
1 Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992; 44 (3) 527-32
2 Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother. 2005; 6 (5) 755-64
3 Savia P, Herbert JM, Pfliegera AM, Dola F, Delebasseea D, Combalberta J et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992; 44 (3) 527-32
4 Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of Clopidogrel. Semin Thromb Hemost. 1999; 25 (02) 25-8
5 Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P et al. structure and stereochemistry of the active metabolite of Clopidogrel. Drug Metab Dispos. 2002; 30 (11) 1288-95
6 Singhal D, Curatolo W.. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliver Rev. 2004; 56: 335-47
7 Lifshits-Liron R, Kovalevski-Ishai E, Wizel S, Avhar-Maydar S, Lidor-Hadas R. Kenyon & Kenyon. Polymorphs of Clopidogrel hydrogensulfate, United States patent US 0225129 2003 Dec 4
8 Lohray BB, Lohray VB, Pandey B, Dave MG. Nixon & Vanderhye. Polymorphs and amorphous form of (s)-(+)-clopidogrel bisulfate. United States patent US 0037842 2007 Feb 15
9 Singh SS, Sharma K, Barot D, Mohan PR, Lohray VB.. Estimation of carboxylic acid metabolite of Clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 821 (2) 173-80
10 US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry, Bioanalytical Method Validation 2001
11 Rouini MR, Ardakani YH, Foroumadi A, Lavasani H, Hakemi L. Sensitive Quantification of carboxylic acid metabolite of Clopidogrel in human plasma by LC with UV detection. Chromatographia 2009; 70: 953-56
12 Souri E, Jalalizadeh H, Kebriaee-Zadeh A, Dalvandi MSA. Validated HPLC method for determination of carboxylic acid metabolite of Clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2006; 1309: 14
13 Nirogi RVS, Kandikere VN, Shukla M, Mudigonda K, Maurya S et al. Quantification of Clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20: 1695-1700
14 Shin BS, Yoo SD. Determination of Clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. Biomed Chromatogr. 2007; 21: 883-9
15 Ksycinska H, Rudzki P, Bukowska-Kiliszek M. Determination of Clopidogrel metabolite (SR26334) in human plasma by LC–MS. J Pharm Biomed. 2006; 41: 533-9
16 Zou JJ, Fan HW, Guo DQ, Li YB, Lin S, Zhu YB et al. Simultaneous determination of Clopidogrel and its carboxylic acid metabolite (SR26334) in human plasma by LC–ESI–MS–MS: application to the therapeutic drug monitoring of Clopidogrel. Chromatographia 2009; 70: 1581-6
17 Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A.. Quantitative determination of Clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2008; 48 (4) 1219-24
18 Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003; 75 (13) 3019-30
19 Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J. Solid form screening. A review. Eur J Pharm Biopharm. 2009; 71: 23-7